Compare KGC & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KGC | ALC |
|---|---|---|
| Founded | 1993 | 1945 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Ophthalmic Goods |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1B | 39.9B |
| IPO Year | 1994 | 2002 |
| Metric | KGC | ALC |
|---|---|---|
| Price | $30.56 | $77.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $34.83 | ★ $89.38 |
| AVG Volume (30 Days) | ★ 10.0M | 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.42% | 0.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.62 | $8.01 |
| Revenue Next Year | $0.81 | $6.43 |
| P/E Ratio | ★ $24.18 | $38.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.12 | $71.55 |
| 52 Week High | $39.11 | $99.20 |
| Indicator | KGC | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 36.39 | 35.25 |
| Support Level | $26.79 | $77.10 |
| Resistance Level | $38.45 | $77.32 |
| Average True Range (ATR) | 1.37 | 1.71 |
| MACD | -0.49 | -0.82 |
| Stochastic Oscillator | 3.10 | 4.77 |
Kinross Gold is a Canada-based gold producer, producing roughly 2 million gold equivalent ounces in 2025. The company had about a decade of gold reserves at the end of 2025. It operates mines in the Americas and West Africa after selling its low-cost Russian operations in 2022 in response to the invasion of Ukraine. Kinross has historically used acquisitions to fuel expansion into new regions and production growth. In 2022, Kinross purchased the Great Bear project in Canada. If developed as we think likely, it could produce an average of more than 500,000 ounces of gold per year for at least a decade, with its unit cash costs likely in the first quartile of the industry cost curve. Though Great Bear's production is likely to be replacement ounces for falling volumes at other mines.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.